Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60–75 Years: Cancer and Leukemia Group B (CALGB) Study 10502
- Citation:
- Blood vol 116 (abstr 331)
- Meeting Instance:
- ASH 2010
- Year:
- 2010
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Preliminary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 748
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- E. C. Attar K. A. Donohue P. C. Amrein M. Wadleigh D. J. Deangelo J. E. Kolitz B. L. Powell P. M. Voorhees E. S. Wang W. Blum A. Booth R. M. Stone B. K. Moser R. Larson
- Networks:
- Study
- CALGB-10502
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 1/2
- Keywords: